We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.63%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$659M
AUM Growth
-$194M
Cap. Flow
-$205M
Cap. Flow %
-31.16%
Top 10 Hldgs %
43.01%
Holding
164
New
28
Increased
30
Reduced
27
Closed
56

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$15.1M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
FOLD
Amicus Therapeutics
FOLD
+$11.3M
4
NMTR
9 Meters Biopharma
NMTR
+$9.54M
5
MRK icon
Merck
MRK
+$8.77M

Top Sells

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.22M
4
RXDX
Ignyta, Inc.
RXDX
+$9.19M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 75.21%
2 Technology 4.55%
3 Financials 1.71%
4 Communication Services 1.32%
5 Consumer Discretionary 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
126
KALA BIO
KALA
$14.1M
– –
-40
Closed -$1.85M
LOW icon
127
Lowe's Companies
LOW
$117B
– –
-2,600
Closed -$242K
NBIX icon
128
Neurocrine Biosciences
NBIX
$16.8B
– –
-37,000
Closed -$2.87M
NOMD icon
129
Nomad Foods
NOMD
$1.66B
– –
-340,162
Closed -$5.75M
OVID icon
130
Ovid Therapeutics
OVID
$414M
– –
-180,674
Closed -$1.78M
PANW icon
131
Palo Alto Networks
PANW
$270B
– –
-96,330
Closed -$2.33M
PDSB icon
132
PDS Biotechnology
PDSB
$38.4M
– –
-16,687
Closed -$3.13M
PRTA icon
133
Prothena Corp
PRTA
$425M
– –
-205,000
Closed -$7.68M
RNAC icon
134
Cartesian Therapeutics
RNAC
$229M
– –
-7,618
Closed -$2.24M
SAGE
135
DELISTED
Sage Therapeutics
SAGE
– –
-30,000
Closed -$4.94M
SAGE
136
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-2,400
Closed -$395K
DCOY
137
Decoy Therapeutics
DCOY
$2.19M
– –
0
– -$4.34M
SMMT icon
138
Summit Therapeutics
SMMT
$10.4B
– –
-212,018
Closed -$2.35M
SVRA icon
139
Savara
SVRA
$1.12B
– –
-200,000
Closed -$2.97M
TEVA icon
140
Teva Pharmaceuticals
TEVA
$40.8B
– –
-118,750
Closed -$2.25M
TJX icon
141
TJX Companies
TJX
$174B
– –
-11,600
Closed -$443K
TRIP icon
142
TripAdvisor
TRIP
$1.65B
– –
-4,000
Closed -$138K
TXMD icon
143
TherapeuticsMD
TXMD
$23.5M
– –
-9,600
Closed -$2.9M
VRTX icon
144
Vertex Pharmaceuticals
VRTX
$121B
– –
-85,823
Closed -$12.9M
VTRS icon
145
CALL
Viatris
VTRS
$20.4B
– –
-50,000
Closed -$2.12M
WIX icon
146
WIX.com
WIX
$2.3B
– –
-78,180
Closed -$4.5M
XLF icon
147
State Street Financial Select Sector SPDR ETF
XLF
$56.7B
– –
-155,000
Closed -$4.33M
RNTX
148
Rein Therapeutics
RNTX
$63.1M
– –
-6,250
Closed -$1.32M
CBAY
149
DELISTED
Cymabay Therapeutics
CBAY
– –
-240,000
Closed -$2.21M
IMGN
150
DELISTED
Immunogen Inc
IMGN
– –
-500,000
Closed -$3.21M
3 4 5
6
7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sphera Funds Management held 164 positions worth $659M, down 23% from $852M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Sphera Funds Management withdrew a net $205M in Q1 2018, closing 56 positions and reducing 27 holdings. Its most notable exit was Cellcom Israel, Ltd., an estimated $14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 59% a quarter earlier, followed by Technology and Financials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $14.3M.

  • Sphera Funds Management's largest Q1 2018 buy was Regeneron Pharmaceuticals: 41,500 shares worth $14.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2018, an estimated $15.1M increase.
  • Sphera Funds Management's biggest Q1 2018 reduction was Sarepta Therapeutics, cutting an estimated $9.07M.
  • Sphera Funds Management fully exited Cellcom Israel, Ltd. in Q1 2018, selling an estimated $14M.
  • Sphera Funds Management's ten largest holdings make up 43% of its $659M portfolio in Q1 2018.
  • Sphera Funds Management opened 28 new positions and closed 56 in Q1 2018.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $659M.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.